Feng Zhou
13Patents
2h-index
36Co-inventors
50Inventor score
Filing activity: Aug 1, 2013 → Dec 20, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10464927B2 | 2,4-disubstituted pyrimidines as CDK inhibitors | Chemistry; Metallurgy | 5 | Active |
| US10973805B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Chemistry; Metallurgy | 4 | Active |
| US11225497B2 | Prodrugs of a CDK inhibitor for treating cancers | Emerging Cross-Sectional Technologies | 1 | Active |
| US11590111B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Chemistry; Metallurgy | 1 | Active |
| US10881681B2 | CD73 inhibitors and pharmaceutical uses thereof | Chemistry; Metallurgy | 1 | Active |
| US11530234B2 | CD73 inhibitors and pharmaceutical uses thereof | Human Necessities | 0 | Active |
| US11814405B2 | Pyridine sulfonamide phosphate compound, preparation method therefor, and use thereof | Chemistry; Metallurgy | 0 | Active |
| US12421238B2 | Selective dihydropyrrolopyrimidine JAK2 inhibitors | Chemistry; Metallurgy | 0 | Active |
| US10351578B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | Chemistry; Metallurgy | 0 | Active |
| US12247015B2 | 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 | Human Necessities | 0 | Active |
| US11725020B2 | Prodrugs of a CDK inhibitor for treating cancers | Emerging Cross-Sectional Technologies | 0 | Active |
| US12109198B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Chemistry; Metallurgy | 0 | Active |
| US9695175B2 | Highly selective c-Met inhibitors as anticancer agents | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.